Genmab achieved positive results from a Phase II study of Arzerra (ofatumumab) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in front line follicular non-Hodgkin’s lymphoma (NHL). The study included a total of 58 patients with previously untreated NHL. The overall response rate (ORR) in patients treated with 500 mg of ofatumumab was 90%, including 24% complete remissions (CR), and 45% complete remissions/unconfirmed (CRu). In patients treated with ...